---
title: "Obefazimod (ABX464) in Ulcerative colitis: Anti-integrin antibodies"
description: "Formulary evidence on Obefazimod (ABX464) in Ulcerative colitis: Anti-integrin antibodies. Topics: Recommendations for vedolizumab: ACG 2025 guideline, Pivotal trial efficacy of vedolizumab: ACG 2025 guideline, VARSITY head-to-head trial and comparative safety: AGA 2024 living guideline, Efficacy of vedolizumab by prior biologic exposure: AGA 2024 network meta-analysis, and 3 further topics. 7 evidence topics quoted from 6 sources."
canonical: "https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/product-information-and-disease-description/anti-integrin-antibodies"
published: "2026-11-18T10:42:55-05:00"
modified: "2026-11-18T10:42:55-05:00"
---

# Obefazimod (ABX464) in Ulcerative colitis: Anti-integrin antibodies

<a id="heading-2.2.2.1.5"></a>

## 2.2.2.1.5 Anti-integrin Antibodies

<a id="topic-2.2.2.1.5-1"></a>

### Recommendations for vedolizumab: ACG 2025 guideline

> “27. In patients with moderately to severely active UC, we recommend vedolizumab for induction of remission (Strong recommendation, moderate quality of evidence).”
> “41. We recommend continuing vedolizumab as compared with no treatment for maintenance of remission (intravenous [IV] or subcutaneous [SC] dosing) in patients with prior moderately to severely active UC now in remission after vedolizumab induction (Strong recommendation, moderate quality of evidence).”
> “45. In patients with moderately to severely active UC, we recommend vedolizumab as compared with adalimumab for induction and maintenance of remission (Strong recommendation, moderate quality of evidence).”

Source: [Rubin et al. (2025)](https://journals.lww.com/ajg/fulltext/10.14309/ajg.0000000000003463)

<a id="topic-2.2.2.1.5-2"></a>

### Pivotal trial efficacy of vedolizumab: ACG 2025 guideline

> “In the comparison cohort, 16.9% and 40.9% of patients receiving vedolizumab achieved clinical remission and mucosal healing at week 6, respectively, compared with 5.4% and 24.8% of patients receiving placebo (P = 0.001 for both comparisons).”
> “A total of 40% of patients receiving vedolizumab maintained remission at week 52 compared with 16% of patients who received placebo (192).”
> “Clinical remission at week 52 was achieved by 46.2%, 42.6%, and 14.3% of patients in the SC vedolizumab, intravenous vedolizumab, and placebo groups, respectively (vedolizumab SC vs placebo, P < 0.001) (197).”

Source: [Rubin et al. (2025)](https://journals.lww.com/ajg/fulltext/10.14309/ajg.0000000000003463)

<a id="topic-2.2.2.1.5-3"></a>

### VARSITY head-to-head trial and comparative safety: AGA 2024 living guideline

> “The only head-to-head trial was the VARSITY trial where 769 patients with moderate-to-severe UC were randomized to receive either vedolizumab (n=383) or adalimumab (n=386)38. At week 52, a higher rate of clinical remission was observed in the vedolizumab treated patients (31.3%) compared to adalimumab (22.5%). Corticosteroid-free remission rates, however, were higher with adalimumab (21.8%) compared to vedolizumab (12.6%).”
> “This trial noted no difference between the two agents in maintaining clinical remission (20.3% vs 16.0%) in this subpopulation.”
> “In observational studies, vedolizumab was associated with a lower risk of serious infections compared with TNF antagonists in patients with UC69, 70; there was paucity of evidence for comparative safety of other agents.”

Source: [Singh et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12162142/)

<a id="topic-2.2.2.1.5-4"></a>

### Efficacy of vedolizumab by prior biologic exposure: AGA 2024 network meta-analysis

> “Intriguingly, the difference in relative efficacy of a drug in biologic-exposed vs. biologic-naïve patients was significantly greater for some drugs, most notably for vedolizumab and ozanimod in our analysis.”

Source: [Ananthakrishnan et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12148344/)

<a id="topic-2.2.2.1.5-5"></a>

### Recommendations and meta-analysis for vedolizumab: ECCO 2026 guideline

> “We recommend treatment with vedolizumab for the induction of remission in moderate-to-severe ulcerative colitis [strong recommendation, low certainty of evidence] [Agreement: 100%]”
> “We recommend vedolizumab for the maintenance of remission in patients with ulcerative colitis who responded to induction therapy with vedolizumab [strong recommendation, moderate certainty of evidence] [Agreement: 100%]”
> “We suggest the use of vedolizumab rather than adalimumab for the induction and maintenance of remission in moderate-to-severe ulcerative colitis [weak recommendation, low certainty of evidence] [Agreement: 100%]”
> “Induction responders who subsequently received vedolizumab were more likely to achieve clinical remission than those receiving placebo after 52–60 weeks of follow-up [RR: 2.37; 95% CI: 1.74–3.23].”
> “Rates of SAEs in patients treated with vedolizumab were not significantly different from those receiving placebo [RR: 0.71; 95% CI: 0.39–1.30].”
> “In the subgroup analysis, the results were statistically significant in biologic-naive patients and only numerically superior in the biologic-exposed population.”

Source: [Gisbert et al. (2026)](https://academic.oup.com/ecco-jcc/article/20/7/jjag066/8726617)

<a id="topic-2.2.2.1.5-6"></a>

### Comparative clinical effectiveness of vedolizumab: ICER 2026 special assessment

> “We rated Entyvio as comparable or inferior to ustekinumab (C-).”
> “Entyvio was rated comparable or better than the anti-TNF drugs infliximab and adalimumab (C+).”
> “However, there were fewer serious infections with Entyvio in observational data, and both infliximab and adalimumab carry black box warnings for serious infections and malignancies.”

Source: [ICER special assessment of Entyvio to inform CMS negotiation (2026)](https://icer.org/wp-content/uploads/2026/03/Entyvio_Final-Evidence-Report_For-Publication_030326.pdf)

<a id="topic-2.2.2.1.5-7"></a>

### Indication and warnings for vedolizumab

> “ENTYVIO is an integrin receptor antagonist indicated in adults for the treatment of:”
> “moderately to severely active ulcerative colitis (UC).”
> “Discontinue ENTYVIO in patients who do not show evidence of therapeutic benefit by Week 14.”
> “Progressive Multifocal Leukoencephalopathy (PML): Although unlikely, a risk of PML cannot be ruled out. Monitor patients for any new or worsening neurological signs or symptoms.”

Source: [Entyvio prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/125476s66lbl.pdf)

## Related pages
- [Obefazimod (ABX464): Ulcerative colitis](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Terms and abbreviations](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/terms-and-abbreviations.md)
- [Obefazimod (ABX464): Ulcerative colitis](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/executive-summary.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Product information and disease description](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/product-information-and-disease-description.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Clinical evidence](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/clinical-evidence.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Economic information and modeling report](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/economics) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/economics.md)
- [Obefazimod (ABX464) in Ulcerative colitis: References](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/references) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/references.md)
